Tabrecta

Generic Name: capmatinib

Drug Class: Targeted Therapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Drug Indication

Tabrecta is a kinase inhibitor approved for the treatment of metastatic non-small-cell lung cancer with a specific genetic mutation.

General Info



Tabrecta targets the MET (mesenchymal-epithelial transition) enzyme, which plays a role in cell development. A gene mutation known as exon 14 skipping leads to greater MET activity, which drives cancer growth.

The GEOMETRY trial showed that Tabrecta shrank tumors in 68% of people with metastatic non-small-cell lung cancer with a confirmed MET exon 14 skipping mutation. The response rate was 41% in a subset of patients who had been previously treated. Tabrecta was first approved in May 2020.

Dosage

Dosing Info:

Tabrecta is taken as a tablet twice daily with or without food.

Side Effects

Common adverse reactions include swelling, nausea, vomiting, decreased appetite, fatigue and shortness of breath. Potential serious side effects may include lung inflammation (pneumonitis), liver toxicity and sensitivity to light (photosensitivity), which can lead to severe sunburn. Tabrecta can cause fetal harm if used during pregnancy.

For More Info: https://www.us.tabrecta.com/

Last Reviewed: May 7, 2020

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.cancerhealth.com/drug/tabrecta